HIPAA Could Prevent Future Genzyme Marker Study For Knee Defects
This article was originally published in The Gray Sheet
Executive Summary
The Health Insurance Portability & Accountability Act of 1996 may represent an obstacle to effectiveness testing of tissue products for the repair or replacement of articular cartilage defects in the knee
You may also be interested in...
FDA Issues Guidance On IDEs For Knee Cartilage Replacement
Investigational device exemption (IDE) applications for knee cartilage replacement products should include a detailed product description, manufacturing and packaging methodology, and nonclinical testing data to assess biological responses and toxicology, FDA advises in a July 9 1draft guidance
FDA Issues Guidance On IDEs For Knee Cartilage Replacement
Investigational device exemption (IDE) applications for knee cartilage replacement products should include a detailed product description, manufacturing and packaging methodology, and nonclinical testing data to assess biological responses and toxicology, FDA advises in a July 9 1draft guidance
CDRH Division Director Witten Leaves Device Center To Lead CBER Office
Miriam Provost, PhD, is serving as acting head of the device center's Division of General, Restorative & Neurological Devices (DGRND) following the departure of division director Celia Witten